Clinical trial

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

NCT02705339

Study summary

ClinicalTrials.gov

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Rociletinib Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Biopsy Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Blood draw Find medicine records · Find other trials using this name

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2016-05-01

PhasePHASE2

Conditions

Carcinoma, Non-Small-Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Nonsmall Cell Lung Cancerverified · MONDO: tumor suppressor gene on chromosome 11

Interventions

RociletinibDRUG

BiopsyPROCEDURE

Blood drawPROCEDURE

Sponsors & collaborators

Washington University School of Medicinelead sponsor

Clovis Oncology, Inc.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02705339 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.